The U.S. Food and Drug Administration has approved a new drug, Daraxonrasib, for the treatment of metastatic pancreatic cancer, marking a significant milestone in the fight against this deadly disease. This landmark approval is expected to transform the treatment landscape, offering new hope to patients by nearly doubling life expectancy. This first-in-class therapy, developed by Revolution Medicines, is seen as a game changer in addressing one of the most challenging cancers, as it targets specific mutations that drive tumor growth. The expedited approval reflects both its promising trial results and the urgent need for effective treatment options in a disease with high mortality rates.